IP Library Granted Patent US 10,730,912
Granted Patent B2
US 10,730,912 · App. 15/392,586 · Granted Aug 4, 2020

Template-fixed peptidomimetics with antimicrobial activity

Inventors: Steven J. Demarco (Dietgen, CH); Wim Vrijbloed (Moehlin, CH); Ricardo Dias (Binningen, CH); John Anthony Robinson (Wermatswil, CH); Nityakalyani Srinivas (Basel, CH); Frank Gombert (Huttingen, DE); Daniel Obrecht (Baettwil, CH)
Assignees: POLYPHOR LTD.; UNIVERSITAET ZUERICH
C07K7/64A01N43/36C07K1/10C07K7/06C07K7/08C07K14/001A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,730,912
App. No.
15/392,586
Granted
Aug 4, 2020
Kind
B2
Abstract

Template-fixed β-hairpin peptidomimetics of the general formula wherein Z is a template-fixed chain of 12 α-amino acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid) are Gly, or Pro, or of certain types which, as the remaining symbols in the above formula, are defined in the description and the claims, and salts thereof, have the property to selectively inhibit the growth of or to kill microorganisms such as Pseudomonas aeruginosa . They can be used as disinfectants for foodstuffs, cosmetics, medicaments or other nutrient-containing materials, or as medicaments to treat or prevent infections. These β-hairpin peptidomimetics can be manufactured by processes which are based on a mixed solid- and solution phase synthetic strategy.

Claims (59)

1. A compound represented by the following formula (I):

is D Pro- L Pro or L Pro- D Pro and Z is a chain of 12 α-amino acid residues, wherein the positions of the amino acid residues in the chain are counted starting from the N-terminal amino acid, wherein the amino acid residues in positions P1 to P12 of the chain are

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Ala, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Gly, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, D Ala, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, D Val, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Aib, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Abu, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Leu, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Ile, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Nle, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Nva, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Chg, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Cha, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Gln, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Asp; Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Glu, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Thr, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Pro, Dab;

Cit, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Ala, Dab;

Thr, Tyr, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Ala, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Tyr, Dab, Dab, Ala, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, His, Trp, Dab, Dab, Ala, Dab;

Ala, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Ala, Dab;

Ala, Trp, Ile, Dab, Dab, Dab, Dab, Trp, Dab, Dab, Val, Dab;

Thr, Trp, Ile, Lys, Lys, Dab, Dab, Trp, Dab, Dab, Ala, Dab;

Thr, Trp, Ile, Dab, Lys, Lys, Dab, Trp, Dab, Dab, Ala, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Lys, Trp, Dab, Dab, Ala, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Lys, Dab, Ala, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Ala, Lys;

Thr, Trp, Ile, Gln, Lys, Dab, Dab, Trp, Dab, Dab, Ala, Dab;

Thr, Trp, Ile, Gln, Lys, Dab, Dab, Trp, Dab, Dab, Val, Dab;

Thr, Trp, Nle, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Ala, Dab;

Thr, Trp, Val, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Ala, Dab;

Thr, Trp, Chg, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Ala, Dab;

Thr, Trp, Cha; Dab, Lys, Dab, Dab, Trp, Dab, Dab, Ala, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Hse, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, t-BuG, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Cpa, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Asn, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Gln, Trp, Dab, Dab, Ala, Dab;

Thr, Trp, Ile, Gln, Lys, Dab, Dab, Trp, Dab, Dab, Ala, Gln;

Thr, Trp, Ile, Dab, Lys, D Dab, Dab, Trp, Dab, Dab, Ala, Dab;

Asp, Tyr, Ile, Dab, Lys, D Dab, Dab, Trp, Dab, Dab, Ala, Dab;

Asp, Tyr, Ile, Dab, Orn, D Dab, Dab, Trp, Dab, Dab, Ala, Dab;

Glu, Trp, Ile, Dab, Lys, D Dab, Dab, Trp, Dab, Dab, Ala, Dab;

Glu, Trp, Ile, Dab, Lys, D Dab, Dab, Trp, Dab, Dab, Ala, Gln;

Glu, Trp, Ile, Dab, Lys, D Dab, Dab, Trp, Dab, Dab, Ala, Dap;

Glu, Trp, Ile, Dab, Orn, D Dab, Dab, Trp, Dab, Dab, Ala, Dab;

Thr, Trp, Ile, Dab, Orn, D Dab, Dab, Trp, Dab, Dab, Ala, Dab;

Thr, Trp, Ile, Dab, Orn, D Dab, Dab, Trp, Dab, Dab, Ala, Ser; or

Glu, Trp, Ile, Gln, Lys, Dab, Dab, Ser, Dab, Dab, Ala, Ser,

or a pharmaceutically acceptable salt or enantiomer thereof.

2. An enantiomer of the compound of claim 1 or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 or a pharmaceutically acceptable salt thereof, which is therapeutically active.

4. The compound of claim 1 or a pharmaceutically acceptable salt thereof, which has selective antimicrobial activity against Pseudomonas aeruginosa.

5. A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically inert carrier.

6. The pharmaceutical composition of claim 5 , which is in a form suitable for oral, topical, transdermal, injection, buccal, transmucosal, pulmonary, or inhalation administration.

7. The pharmaceutical composition of claim 5 , which is in the form of a tablet, dragee, capsule, solution, liquid, gel, plaster, cream, ointment, syrup, slurry, suspension, spray, nebuliser, or suppository.

Assignments (3)
SECURITY INTEREST Recorded May 4, 2023
From: ENBIOTIX (SWITZERLAND) GMBH
To: SPRIM GLOBAL INVESTMENTS PTE. LTD
Reel/Frame 063531/0455 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 19, 2023
From: DEMARCO, STEVEN J.; VRIJBLOED, WIM; DIAS, RICARDO; ROBINSON, JOHN ANTHONY; SRINIVAS, NIRYAKALYANI; GOMBERT, FRANK; OBRECHT, DANIEL
To: POLYPHOR LTD.; UNIVERSITAET ZUERICH
Reel/Frame 063376/0232 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 19, 2023
From: POLYPHOR LTD.
To: ENBIOTIX (SWITZERLAND) GMBH
Reel/Frame 063376/0430 →
Priority Claims (1)
WO PCT/CH2006/00036 · Jan 16, 2006 · international
Continuity (3)
Division 14175193 · Feb 7, 2014
Division 12161065
Related Publication 20170107259A1 · Apr 20, 2017